← Leaderboards
Jiyang Yu
St. Jude Children'S Research Hospital
$5,075,926
Attributed
$8,437,279
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,437,279 · 5
By mechanism
U01$5,192,638 · 2
R01$2,870,185 · 2
R03$374,456 · 1
Top collaborators
- Jun J. Yang6 shared
- Hongbo Chi3 shared
- Jose M Silva2 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Suzanne J Baker$15,879,154
- Jun J. Yang$13,116,250
- Charles G. Mullighan$25,123,215
- Paul Northcott$7,792,208
- Giedre Krenciute$4,894,202
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularGenomicsIn VivoMediatingCellsResistanceTumorSingle-Cell Rna SequencingSystems BiologySignal TransductionNetwork-BasedTargeted TreatmentCell CommunicationMapsSaint Jude Children&AposS Research HospitalHeterogeneityIn VitroClinical TrialsAlgorithmsSamplingDrug ResistanceDrug SensitivityClustered Regularly Interspaced Short Palindromic Repeats
Grant awards (16)
Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology$819,000
U01 · FY2025 · CA
Investigating the Molecular Determinants Driving Response and Resistance to HDAC6 Targeted Therapy in Breast Cancer$569,181
R01 · FY2025 · CA
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia$528,622
U01 · FY2025 · CA · contact PI
Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology$778,050
U01 · FY2024 · CA
Investigating the Molecular Determinants Driving Response and Resistance to HDAC6 Targeted Therapy in Breast Cancer$586,431
R01 · FY2024 · CA
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia$501,244
U01 · FY2024 · CA · contact PI
Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology$819,000
U01 · FY2023 · CA
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia$518,050
U01 · FY2023 · CA · contact PI
Intracellular and Intercellular Network Rewiring and Hidden Driver Inference from Single-Cell Data$339,854
R01 · FY2023 · GM · contact PI
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia$700,050
U01 · FY2022 · CA · contact PI
Intracellular and Intercellular Network Rewiring and Hidden Driver Inference from Single-Cell Data$339,854
R01 · FY2022 · GM · contact PI
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia$528,622
U01 · FY2021 · CA · contact PI
Intracellular and Intercellular Network Rewiring and Hidden Driver Inference from Single-Cell Data$339,854
R01 · FY2021 · GM · contact PI
Systems biology analyses to identify driver genes in Down syndrome-related ALL$374,456
R03 · FY2020 · HD
Intracellular and Intercellular Network Rewiring and Hidden Driver Inference from Single-Cell Data$339,854
R01 · FY2020 · GM · contact PI
Intracellular and Intercellular Network Rewiring and Hidden Driver Inference from Single-Cell Data$355,157
R01 · FY2019 · GM · contact PI